left-arrow right-arrow pinterest facebook google_plus linkedin

AFT-39

Status:

Recruiting | Phase Not Applicable 

Official Title:

Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)

Study Purpose:

To determine if having patients report their symptoms of cancer treatment electronically on weekly basis will benefit patients more than patient report symptoms at appointments, and gather perspectives on reporting symptoms online or over the phone from patients and staff.

Interventions:

Patients will use an online system or automated phone system to report their symptoms on a weekly basis for up to 12 months or until treatment is discontinued

  • Quality of Life questionnaires

After completion of study therapy, patients are followed up on at 18 months and 24 months from enrollment

Key Participation Requirements:

Gender:

Male or Female

Age:

21 years and older

Diagnosis:

Patients with advanced or metastatic cancer of ANY type except leukemia or indolent lymphoma.

Eligibility:

Patients must be receiving outpatient cancer treatment that is being used to control a cancer or reduce its symptoms but not cure it, including chemotherapy, targeted therapy, or immunotherapy.

Patients being treated with curative intent are not eligible

Patients receiving hormonal therapy only are not eligible

Patients can be at ANY point of their treatment.

Patients must be able to understand English, Spanish, or Mandarin Chinese.

Patients must not be participating in any other clinical trial

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

AFT-39

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!